Cohance Life

{
  "main_header": {
    "sid": 1003386,
    "name": "Cohance Life",
    "stock_name": "Cohance Life",
    "full_name": "Cohance Lifesciences Ltd",
    "name_url": "stocks-analysis/cohance-life",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 1,
    "country_id": 34,
    "currency": "INR",
    "cmp": "405.75",
    "chg": -8.25,
    "chgp": "-1.99%",
    "dir": -1,
    "prev_price": "414.00",
    "mcapval": "15,553.00 Cr",
    "mcap": "Small Cap",
    "scripcode": 543064,
    "symbol": "COHANCE",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "sector_id": 65,
    "indexname": "India SENSEX",
    "isin": "INE03QK01018",
    "curr_date": "Jun 19, 03:30 PM",
    "curr_time": "23:04 PM",
    "last_traded_at": "Jun 19, 03:30 PM IST",
    "bse_nse_vol": "8.3 lacs",
    "exc_status": "Active",
    "traded_date": "Jun 19, 2026",
    "traded_date_str": "2026 06 19",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/cohance-life-1003386-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Cohance Lifesciences Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/cohance-lifesciences-ltd-is-rated-strong-sell-4063096",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/CohanceLifescie_mojoScore_4063096.png",
        "date": "2026-06-19 10:10:57",
        "description": "Cohance Lifesciences Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 14 May 2026. However, the analysis and financial metrics presented here reflect the company’s current position as of 19 June 2026, providing investors with the most up-to-date view of the stock’s fundamentals, returns, and technical outlook."
      },
      {
        "title": "Cohance Lifesciences Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/cohance-lifesciences-ltd-is-rated-strong-sell-4037300",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/CohanceLifescie_mojoScore_4037300.png",
        "date": "2026-06-08 10:10:40",
        "description": "Cohance Lifesciences Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 14 May 2026, reflecting a significant reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed below are current as of 08 June 2026, providing investors with the latest perspective on the company’s position."
      },
      {
        "title": "Cohance Lifesciences Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/cohance-lifesciences-ltd-is-rated-strong-sell-4037317",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/CohanceLifescie_mojoScore_4037317.png",
        "date": "2026-06-07 10:10:33",
        "description": "Cohance Lifesciences Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 14 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 08 June 2026, providing investors with an up-to-date perspective on the company’s performance and outlook."
      },
      {
        "title": "Cohance Lifesciences Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/cohance-lifesciences-ltd-is-rated-strong-sell-4037303",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/CohanceLifescie_mojoScore_4037303.png",
        "date": "2026-06-06 10:10:33",
        "description": "Cohance Lifesciences Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 14 May 2026. However, the analysis and financial metrics presented here reflect the stock’s current position as of 08 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and overall outlook."
      },
      {
        "title": "Cohance Lifesciences Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/cohance-lifesciences-ltd-is-rated-strong-sell-4037222",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/CohanceLifescie_mojoScore_4037222.png",
        "date": "2026-06-05 10:10:38",
        "description": "Cohance Lifesciences Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 14 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 08 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing."
      },
      {
        "title": "Cohance Lifesciences Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/cohance-lifesciences-ltd-is-rated-strong-sell-4010251",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/CohanceLifescie_mojoScore_4010251.png",
        "date": "2026-05-25 10:10:41",
        "description": "Cohance Lifesciences Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 14 May 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 25 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and overall outlook."
      },
      {
        "title": "Cohance Lifesciences Ltd Surges 7.57% to Day's High of Rs 458.8 — Outperforms Sector by 4.75 Percentage Points",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cohance-lifesciences-ltd-hits-intraday-high-with-757-surge-on-19-may-2026-3998541",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/CohanceLifescie_priceRelatedfactors_3998541.png",
        "date": "2026-05-19 09:32:00",
        "description": "The Sensex edged up 0.51% on 19 May 2026, but Cohance Lifesciences Ltd outpaced the broader market with a robust 7.57% gain, marking a 4.75 percentage-point outperformance over its Pharmaceuticals & Biotechnology sector peers. This sharp intraday advance rewrites the short-term narrative for the small-cap stock, raising questions about whether this is a genuine recovery or a technical bounce within a mixed trend."
      },
      {
        "title": "Cohance Lifesciences Ltd Falls 13.33%: 5 Key Factors Driving the Weekly Decline",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cohance-lifesciences-ltd-falls-1333-5-key-factors-driving-the-weekly-decline-3994194",
        "imagepath": "",
        "date": "2026-05-16 12:00:59",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>11 May:</strong> Stock opens at ₹478.65, down 1.98% amid broader market weakness</p>\n                    <p><strong>12 May:</strong> Technical momentum shifts amid mixed market signals, stock gains 1.48%</p>\n                    <p><strong>13 May:</strong> Significant gap down opening and Q4 FY26 results reveal 84% profit plunge</p>\n                    <p><strong>14 May:</strong> Continued financial struggles reported; valuation shifts signal price attractiveness change</p>\n                    <p><strong>15 May:</strong> Week closes at ₹423.20, down 4.94% on the day and 13.33% for the week</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div ..."
      },
      {
        "title": "Cohance Lifesciences Ltd Reports Continued Financial Struggles Amidst Sector Challenges",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/cohance-lifesciences-ltd-reports-continued-financial-struggles-amidst-sector-challenges-3991221",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/CohanceLifescie_fintrenddot_3991221.png",
        "date": "2026-05-14 11:00:14",
        "description": "Cohance Lifesciences Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has reported a further deterioration in its financial performance for the quarter ended March 2026. Despite a marginal improvement in its financial trend score, the company continues to face significant headwinds, with sharp declines in profitability and sales growth contrasting starkly with broader market benchmarks."
      }
    ],
    "total": 573,
    "sid": "1003386",
    "stock_news_url": "https://www.marketsmojo.com/news/cohance-lifesciences-1003386"
  },
  "announcements": [
    {
      "caption": "Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011",
      "datetime": "18-Jun-2026",
      "details": "The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 on June 17 2026 for Jusmiral Holdings Ltd & Others",
      "source": "BSE"
    },
    {
      "caption": "Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations 2011.",
      "datetime": "18-Jun-2026",
      "details": "The Exchange has received the Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations 2011 on June 17 2026 for Jusmiral Holdings Ltd & Others",
      "source": "BSE"
    },
    {
      "caption": "Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011",
      "datetime": "18-Jun-2026",
      "details": "The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 on June 17 2026 for Jusmiral Holdings Ltd & Others",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Cohance Lifesciences Ltd has declared <strong>100%</strong> dividend, ex-date: 09 Sep 22",
          "dt": "2022-09-09",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "",
      "data": [
        {
          "txt": "Cohance Lifesciences Ltd has announced <strong>1:1</strong> bonus issue, ex-date: 25 Sep 20",
          "dt": "2020-09-25",
          "middle_text": "Bonus Alert"
        }
      ]
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Cohance Lifesciences Ltd is Rated Strong Sell

2026-06-19 10:10:57

Cohance Lifesciences Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 14 May 2026. However, the analysis and financial metrics presented here reflect the company’s current position as of 19 June 2026, providing investors with the most up-to-date view of the stock’s fundamentals, returns, and technical outlook.

Read full news article

Cohance Lifesciences Ltd is Rated Strong Sell

2026-06-08 10:10:40

Cohance Lifesciences Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 14 May 2026, reflecting a significant reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed below are current as of 08 June 2026, providing investors with the latest perspective on the company’s position.

Read full news article

Cohance Lifesciences Ltd is Rated Strong Sell

2026-06-07 10:10:33

Cohance Lifesciences Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 14 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 08 June 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.

Read full news article

Cohance Lifesciences Ltd is Rated Strong Sell

2026-06-06 10:10:33

Cohance Lifesciences Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 14 May 2026. However, the analysis and financial metrics presented here reflect the stock’s current position as of 08 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and overall outlook.

Read full news article

Cohance Lifesciences Ltd is Rated Strong Sell

2026-06-05 10:10:38

Cohance Lifesciences Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 14 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 08 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Read full news article

Cohance Lifesciences Ltd is Rated Strong Sell

2026-05-25 10:10:41

Cohance Lifesciences Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 14 May 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 25 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and overall outlook.

Read full news article

Cohance Lifesciences Ltd Surges 7.57% to Day's High of Rs 458.8 — Outperforms Sector by 4.75 Percentage Points

2026-05-19 09:32:00

The Sensex edged up 0.51% on 19 May 2026, but Cohance Lifesciences Ltd outpaced the broader market with a robust 7.57% gain, marking a 4.75 percentage-point outperformance over its Pharmaceuticals & Biotechnology sector peers. This sharp intraday advance rewrites the short-term narrative for the small-cap stock, raising questions about whether this is a genuine recovery or a technical bounce within a mixed trend.

Read full news article

Cohance Lifesciences Ltd Falls 13.33%: 5 Key Factors Driving the Weekly Decline

2026-05-16 12:00:59

Key Events This Week

11 May: Stock opens at ₹478.65, down 1.98% amid broader market weakness

12 May: Technical momentum shifts amid mixed market signals, stock gains 1.48%

13 May: Significant gap down opening and Q4 FY26 results reveal 84% profit plunge

14 May: Continued financial struggles reported; valuation shifts signal price attractiveness change

15 May: Week closes at ₹423.20, down 4.94% on the day and 13.33% for the week

Read full news article

Cohance Lifesciences Ltd Reports Continued Financial Struggles Amidst Sector Challenges

2026-05-14 11:00:14

Cohance Lifesciences Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has reported a further deterioration in its financial performance for the quarter ended March 2026. Despite a marginal improvement in its financial trend score, the company continues to face significant headwinds, with sharp declines in profitability and sales growth contrasting starkly with broader market benchmarks.

Read full news article

View All News